These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37899676)

  • 21. Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status.
    Roy PP; Mahtab MA; Rahim MA; Yesmin SS; Islam SB; Akbar SMF
    Euroasian J Hepatogastroenterol; 2022 Jul; 12(Suppl 1):S46-S50. PubMed ID: 36466097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hammerhead-type FXR agonists induce an enhancer RNA
    Chen J; Wang R; Xiong F; Sun H; Kemper B; Li W; Kemper J
    Elife; 2024 Apr; 13():. PubMed ID: 38619504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
    Chianelli D; Rucker PV; Roland J; Tully DC; Nelson J; Liu X; Bursulaya B; Hernandez ED; Wu J; Prashad M; Schlama T; Liu Y; Chu A; Schmeits J; Huang DJ; Hill R; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Liu B; Richmond W; Sancho-Martinez I; Phimister A; Seidel HM; Badman MK; Joseph SB; Laffitte B; Molteni V
    J Med Chem; 2020 Apr; 63(8):3868-3880. PubMed ID: 31940200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational study of novel natural agonists targeting farnesoid X receptor.
    Hu X; Ge J; Wen Y
    Sci Rep; 2024 Jul; 14(1):17597. PubMed ID: 39079973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.
    Abenavoli L; Falalyeyeva T; Boccuto L; Tsyryuk O; Kobyliak N
    Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30314377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
    Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
    Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.
    Dash A; Figler RA; Blackman BR; Marukian S; Collado MS; Lawson MJ; Hoang SA; Mackey AJ; Manka D; Cole BK; Feaver RE; Sanyal AJ; Wamhoff BR
    Toxicol In Vitro; 2017 Mar; 39():93-103. PubMed ID: 27939613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
    Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
    J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop.
    Kong M; Peng Y; Qiu L
    Acta Biomater; 2023 Jul; 164():435-446. PubMed ID: 37040811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.